Shares of Sanofi (NYSE:SNY) have been given an average recommendation of “Hold” by the sixteen ratings firms that are covering the stock, MarketBeat Ratings reports. Four analysts have rated the stock with a sell recommendation, eight have given a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $49.33.
Several research analysts recently weighed in on SNY shares. Zacks Investment Research cut shares of Sanofi from a “hold” rating to a “sell” rating in a report on Wednesday, February 14th. Deutsche Bank restated a “buy” rating on shares of Sanofi in a report on Monday, April 16th. Barclays cut shares of Sanofi from an “equal weight” rating to an “underweight” rating in a report on Tuesday, January 23rd. TheStreet cut shares of Sanofi from a “b-” rating to a “c+” rating in a report on Tuesday, February 13th. Finally, Liberum Capital upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a report on Friday, March 23rd.
Get Sanofi alerts:
Shares of NYSE SNY opened at $38.89 on Friday. The stock has a market cap of $95.68 billion, a PE ratio of 12.42, a price-to-earnings-growth ratio of 1.82 and a beta of 0.84. Sanofi has a 1 year low of $38.35 and a 1 year high of $38.56. The company has a quick ratio of 1.26, a current ratio of 1.70 and a debt-to-equity ratio of 0.25.
Sanofi (NYSE:SNY) last released its quarterly earnings results on Friday, April 27th. The company reported $0.79 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.05. Sanofi had a net margin of 10.93% and a return on equity of 24.45%. The business had revenue of $7.90 billion for the quarter, compared to analysts’ expectations of $7.88 billion. During the same period in the previous year, the company earned $1.42 earnings per share. The firm’s revenue for the quarter was down 8.7% compared to the same quarter last year. research analysts anticipate that Sanofi will post 3.5 EPS for the current fiscal year.
A number of hedge funds have recently made changes to their positions in the business. Bronfman E.L. Rothschild L.P. raised its position in Sanofi by 46.0% in the fourth quarter. Bronfman E.L. Rothschild L.P. now owns 4,325 shares of the company’s stock worth $186,000 after acquiring an additional 1,362 shares during the period. STA Wealth Management LLC bought a new stake in Sanofi in the fourth quarter worth about $58,996,000. Rockefeller Financial Services Inc. raised its position in Sanofi by 8.4% in the fourth quarter. Rockefeller Financial Services Inc. now owns 18,095 shares of the company’s stock worth $778,000 after acquiring an additional 1,409 shares during the period. Wilbanks Smith & Thomas Asset Management LLC raised its position in Sanofi by 1.9% in the fourth quarter. Wilbanks Smith & Thomas Asset Management LLC now owns 74,467 shares of the company’s stock worth $3,202,000 after acquiring an additional 1,417 shares during the period. Finally, Motco raised its position in Sanofi by 2.2% in the first quarter. Motco now owns 67,326 shares of the company’s stock worth $2,699,000 after acquiring an additional 1,474 shares during the period. 8.68% of the stock is currently owned by institutional investors and hedge funds.
Sanofi Company Profile
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio, an oral immunomodulator and Lemtrada, a monoclonal antibody to treat multiple sclerosis.